Conflict of interest: Nothing to declare.
Thrombophilia testing in children: A 7 year experience
Article first published online: 19 NOV 2013
© 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 3, pages 523–527, March 2014
How to Cite
Mahajerin, A., Obasaju, P., Eckert, G., Vik, T.A., Mehta, R. and Heiny, M. (2014), Thrombophilia testing in children: A 7 year experience. Pediatr. Blood Cancer, 61: 523–527. doi: 10.1002/pbc.24846
Authors' contribution: A.M. designed the study, directed the work, collected data, performed descriptive data analyses, and wrote the manuscript. P.O. conducted primary data collection and performed descriptive data analyses. G.E. performed statistical analyses and contributed to writing the methods. T.V., R.M., and M.H. provided intellectual input to the study design and reviewed the manuscript.
- Issue published online: 15 JAN 2014
- Article first published online: 19 NOV 2013
- Manuscript Accepted: 11 OCT 2013
- Manuscript Received: 6 JUN 2013
- pediatric hematology/oncology;
Incidence of venous thromboembolism (VTE) in children is reported to be increasing. We examined thrombophilia testing results in children with VTE that presented in inpatient and outpatient settings to explore patterns of thrombophilia testing.
Patients/Methods: Children, ages 0–20 years with VTE seen at our institution from Jan 2005 to Apr 2012 were studied retrospectively. All patients with VTE confirmed by imaging were eligible and the presence of significant risk factors was evaluated. Thrombophilia was diagnosed if >1 tests confirmed: persistently low protein C (PC), protein S (PS), and antithrombin (AT) following VTE resolution, persistent antiphospholipid antibodies (APA) positivity >12 weeks from first test, factor V Leiden (FVL) and prothrombin mutation (PTm) hetero- or homozygosity, elevated plasminogen activator inhibitor (PAI-1) levels with 4G/5G or 4G/4G polymorphisms, methylene tetrahydrofolate reductase (MTHFR) polymorphisms with elevated fasting homocysteine levels.
Three hundred ninety-two patients met inclusion criteria. At least one test was ordered in 157/239 inpatients. All 153 outpatients had >1 test ordered. Thrombophilia rate differences between inpatients and outpatients did not reach statistical significance except for PC deficiency, which was significantly higher in outpatients. Of inpatients, central venous line (CVL) was significantly associated with not having tests done (P < 0.0022).
This study of pediatric VTE demonstrated a low thrombophilia rate in both inpatient and outpatient populations. The role of testing in other pediatric patients should be further explored. Pediatr Blood Cancer 2014;61:523–527. © 2013 Wiley Periodicals, Inc.